JCB, Volume 25, Number 2, 2020 Article Vol.25 No. 2 (2020) Using Real Options to Estimate the Pre-commercialisation Value of a Drought Tolerant Wheat Trait Katherine Wynn Uncertainty, sunk investment costs and managerial flexibility means standard investment budgeting methods such as net present value are ineffective and undervalue risky investments. Real Abstract Download PDF Article Vol.25 No. 2 (2020) Bioenterprise Media Strategy 2020: Social Media, Mainstream Coverage, and a New Model of Trust Moira A. Gunn In 2012 and 2016, the first two strategic science-business media models were published (SBBMM 1.0 and 2.0). Since that time, there have been significant changes both to the media landscap Abstract Download PDF Article Vol.25 No. 2 (2020) Post Financial Crisis Transaction Trends of U.S. Biotechnology Firms David R Williams Transactions announcements can signal the health of an industry. This article examines all biotechnology transaction announcements occurring in the U.S. between 2010 and 2017. A baseline Abstract Download PDF Case Study Vol.25 No. 2 (2020) Loss of Control of a Biosimilar Joint Venture and Remeasurement at Fair Value Jennifer Jae-Young Kim Samsung BioLogics recognized a big valuation gain when it lost control over a biosimilar joint venture. The investment community expressed concerns about the revaluation gain because the Abstract Download PDF From the Boardroom Vol.25 No. 2 (2020) Industry drug development portfolio forecasting: productivity, risk, innovation, sustainability Vladimir Shnaydman Multiple factors may affect industry performance, risk, innovation and sustainability in coming years such as long-term economic trends, patents expiration, demographic shifts, and regula Abstract Download PDF
